Notably, recent preclinical studies have shown that β-arrestin-biased inhibitors such as ACT-777991 can specifically block the infiltration of CXCR3+ CD8+ T cells into the heart, significantly improving survival rates in models of immune checkpoint inhibitor-induced myocarditis (Wang et al., 2022). Here, CD8A is linked to myocarditis.